Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
RAPP Stock Forecast 2026-2027
$41.46
Current Price
$1.98B
Market Cap
Buy 12
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to RAPP Price Targets
+93.0%
To High Target of $80.00
+35.1%
To Median Target of $56.00
-3.5%
To Low Target of $40.00
RAPP Price Momentum
-1.3%
1 Week Change
+8.4%
1 Month Change
+188.3%
1 Year Change
+36.7%
Year-to-Date Change
-5.3%
From 52W High of $43.76
+208.7%
From 52W Low of $13.43
📊 TOP ANALYST CALLS
Did RAPP Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Rapport is one of their latest high-conviction picks.
Latest RAPP Stock Price Targets & Analyst Predictions
Based on our analysis of 3 Wall Street analysts, RAPP has a bullish consensus with a median price target of $56.00 (ranging from $40.00 to $80.00). The overall analyst rating is Strong Buy (9.8/10). Currently trading at $41.46, the median forecast implies a 35.1% upside. This outlook is supported by 12 Buy, 0 Hold, and 0 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
RAPP Analyst Ratings
12
Buy
0
Hold
0
Sell
RAPP Price Target Range
Low
$40.00
Average
$56.00
High
$80.00
Current: $41.46
Latest RAPP Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for RAPP.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Jun 24, 2026 | Leerink Partners | Marc Goodman | Outperform | Initiates | $52.00 |
| May 21, 2026 | BTIG | Buy | Maintains | $N/A | |
| May 19, 2026 | Truist Securities | Danielle Brill | Buy | Assumes | $56.00 |
| May 8, 2026 | BTIG | Buy | Reiterates | $N/A | |
| Apr 22, 2026 | BTIG | Buy | Reiterates | $N/A | |
| Mar 11, 2026 | BTIG | Buy | Maintains | $N/A | |
| Mar 11, 2026 | Wells Fargo | Overweight | Maintains | $N/A | |
| Feb 2, 2026 | Wells Fargo | Overweight | Initiates | $N/A | |
| Dec 9, 2025 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Dec 8, 2025 | BTIG | Buy | Reiterates | $N/A | |
| Nov 19, 2025 | BTIG | Buy | Initiates | $N/A | |
| Nov 7, 2025 | Citizens | Market Outperform | Maintains | $N/A | |
| Sep 16, 2025 | Truist Securities | Buy | Initiates | $N/A | |
| Sep 8, 2025 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Aug 6, 2025 | HC Wainwright & Co. | Buy | Initiates | $N/A | |
| Jul 8, 2025 | JMP Securities | Market Outperform | Reiterates | $N/A | |
| Apr 8, 2025 | JMP Securities | Market Outperform | Initiates | $N/A | |
| Oct 18, 2024 | Jones Trading | Buy | Initiates | $N/A | |
| Jul 2, 2024 | TD Cowen | Buy | Initiates | $N/A | |
| Jul 2, 2024 | Jefferies | Buy | Initiates | $N/A |
Rapport Therapeutics Inc. (RAPP) Competitors
The following stocks are similar to Rapport based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Rapport Therapeutics Inc. (RAPP) Financial Data
Rapport Therapeutics Inc. has a market capitalization of $1.98B with a P/E ratio of 21.2x. The company generates $20.00M in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of -121.1% and return on equity of -28.3%.
Valuation Metrics
Market Cap
$1.98B
Enterprise Value
$1.53B
P/E Ratio
21.2x
PEG Ratio
-0.6x
Price/Sales
99.8x
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
-121.1%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+24.0%
Current Ratio
27.1x
Debt/Equity
2.3x
ROE
-28.3%
ROA
-19.1%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Rapport Therapeutics Inc. (RAPP) Business Model
About Rapport Therapeutics Inc.
What They Do
Develops precision medicines for neurological disorders.
Business Model
Rapport Therapeutics operates as a clinical-stage biopharmaceutical company, generating revenue through the development of targeted small molecule therapeutics that modulate specific neurocircuits. The company focuses on central nervous system disorders and aims to achieve market success through its innovative drug pipeline, particularly with its lead program RAP-219.
Additional Information
Founded in 2022 through a partnership between Third Rock Ventures and Johnson & Johnson Innovation, Rapport is strategically located in Boston and San Diego, which enhances its capacity for innovation in neuromedicine. The company is addressing significant unmet needs in the treatment of disorders such as epilepsy, pain, bipolar disorder, and hearing disorders.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
84
CEO
Mr. Abraham N. Ceesay M.B.A.
Country
United States
IPO Year
N/A
Website
www.rapportrx.comRapport Therapeutics Inc. (RAPP) Latest News & Analysis
Latest News
Quick Summary
COO Cheryl Gault sold 10,000 shares on June 30, 2026, for ~$416,000, reducing her holdings by 6.2% from 159,914 to 149,914 shares at $41.58 per share.
Why It Matters
Cheryl Gault's sale of 10,000 shares indicates potential insider sentiment and may signal confidence concerns about the company's future, impacting stock performance perception.
Source: The Motley Fool
Market Sentiment:
Neutral
Quick Summary
Rapport Therapeutics, Inc. (RAPP) presented at the Goldman Sachs 47th Annual Global Healthcare Conference, showcasing its developments and strategic plans in the healthcare sector.
Why It Matters
Rapport Therapeutics’ presentation at a major healthcare conference may signal its strategic direction and potential growth, influencing investor sentiment and stock performance.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Rapport Therapeutics (Nasdaq: RAPP) will participate in the Jefferies Global Healthcare Conference on June 3, 2026, at 8:45 am ET, focusing on its development of precision medicines.
Why It Matters
Rapport Therapeutics' participation in investor conferences signals active engagement with the investment community, potentially enhancing visibility and attracting interest in its clinical developments.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Rapport Therapeutics Reports First Quarter 2026 Financials and Provides Business Update
2 months ago
Quick Summary
Rapport Therapeutics reported a 90% median reduction in seizures for RAP-219 in Phase 2a trials. Phase 2 trial results for bipolar mania are expected in Q4 2026. The company has $476.8 million in cash.
Why It Matters
Strong Phase 2a data for RAP-219 shows significant seizure reduction, boosting investor confidence. The pipeline's advancement and financial stability suggest growth potential for Rapport Therapeutics.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Rapport Therapeutics, Inc. (RAPP) Reports Q1 Loss
2 months ago
Quick Summary
Rapport Therapeutics, Inc. (RAPP) reported a quarterly loss of $0.42 per share, better than the Zacks estimate of $0.56, and an improvement from a loss of $0.68 per share a year prior.
Why It Matters
RAPP's smaller quarterly loss than expected signals potential operational improvements, possibly boosting investor confidence and affecting stock performance positively.
Source: Zacks Investment Research
Market Sentiment:
Negative
MISE A DISPOSITION DU RAPPORT FINANCIER ANNUEL 2025
2 months ago
Quick Summary
Crossject has released its 2025 annual financial report, now available for public access and filed with the Autorité des Marchés Financiers. The report can be viewed on the company's website.
Why It Matters
Crossject's annual financial report for 2025 reveals insights into its performance and future prospects, particularly regarding ZEPIZURE®, affecting investor sentiment and stock valuation.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About RAPP Stock
What is Rapport Therapeutics Inc.'s (RAPP) stock forecast for 2027?
Based on our analysis of 3 Wall Street analysts, Rapport Therapeutics Inc. (RAPP) has a median price target of $56.00. The highest price target is $80.00 and the lowest is $40.00.
Is RAPP stock a good investment in 2027?
According to current analyst ratings, RAPP has 12 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $41.46. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for RAPP stock?
Wall Street analysts predict RAPP stock could reach $56.00 in the next 12 months. This represents a 35.1% increase from the current price of $41.46. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Rapport Therapeutics Inc.'s business model?
Rapport Therapeutics operates as a clinical-stage biopharmaceutical company, generating revenue through the development of targeted small molecule therapeutics that modulate specific neurocircuits. The company focuses on central nervous system disorders and aims to achieve market success through its innovative drug pipeline, particularly with its lead program RAP-219.
What is the highest forecasted price for RAPP Rapport Therapeutics Inc.?
The highest price target for RAPP is $80.00 from at , which represents a 93.0% increase from the current price of $41.46.
What is the lowest forecasted price for RAPP Rapport Therapeutics Inc.?
The lowest price target for RAPP is $40.00 from at , which represents a -3.5% decrease from the current price of $41.46.
What is the overall RAPP consensus from analysts for Rapport Therapeutics Inc.?
The overall analyst consensus for RAPP is bullish. Out of 3 Wall Street analysts, 12 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $56.00.
How accurate are RAPP stock price projections?
Stock price projections, including those for Rapport Therapeutics Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: July 15, 2026 12:39 PM UTC